Alzheon

The page says the APOE4 allele is a major genetic risk factor for Alzheimer’s disease, with carriers comprising about 65% of patients, and that APOE4 dose-dependently increases soluble beta amyloid oligomer burden.

Valiltramiprosate is an investigational agent that is not approved for use anywhere in the world. The page notes that statements in news stories may be aspirational.

Alzheon provides press releases about its Alzheimer’s drug research and treatment.

Alzheon says its team includes neuroscientists, pharmacologists, clinicians, drug developers and business leaders, and describes its mission as preserving future memories.

Board of Directors Neil Flanzraich, JDExecutive Chairman of the Board of DirectorsChristopher Noel Dunn, MS

Dr. Martin Tolar has held a number of executive positions in life sciences companies, where he has successfully established and grown new companies, business areas and product opportunities.

Scientific Advisory Board Keith Crutcher, PhD University of Cincinnati, Cincinnati, Ohio Volunteer Professor, Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio

Alzheon is a clinical-stage biopharmaceutical company with a Phase 3-ready program in Alzheimer’s disease and a discovery platform of small molecules for the treatment of neurodegenerative disorders.

Contact us Get in touchSend us a message Alzheon, Inc.111 Speen Street, Suite 306Framingham, MA 01701, USA508-861-7709For questions about our clinical studies, please include the study name in your message. NewsletterSign up for

Alzheon is committed to developing breakthrough medicines for patients suffering from Alzheimer's disease and other neurological disorders.

Alzheon, Inc.’s privacy policy describes how it collects, uses, discloses and otherwise processes personal information in connection with the Alzheon.com website.